Helicobacter pylori (Hp) infection is the major cause of gastric inflammation, peptic ulcer disease, and gastric cancer. Recent clinical and in vitro data indicate that the Hp outer inflammatory protein, OipA and the cag pathogenicity island (PAI) are involved in disease pathogenesis based on their ability to induce interleukin (IL)-8 in gastric epithelial cells. Our long term goal is to understand the role(s) of OipA, alone and together with the cag PAI, in the pathogenesis of Hp-related diseases.
In AIM 1, we will determine in vitro molecular mechanisms by which OipA, alone and together with the cag PAI, regulate IL-8 gene transcription. Binding sites for the transcription factors nuclear factor-:B (NF-:B), activator protein 1 (AP-1), interferon-stimulated responsive element (ISRE)-like element, and likely interferon-3 activation sequence (GAS) in the IL-8 promoter are involved in regulating IL-8 gene transcription in Hp-infected gastric epithelial cells. We will use polarized gastric epithelial cells with tight junctions (NCI-N87 cells) to overcome the limitations of non-polarized cells. NCI-N87 cells allow us to detect different cell signaling pathways from the apical membrane (early phase of infection) and basolateral membranes (late phase following opening of tight junctions or epithelial-barrier damage). We will focus on the cell surface receptors epidermal growth factor receptor (EGFR) and G protein coupled receptor (GPCR). In vitro models of Hp infection will be used to clarify 1) overall signaling pathways from the cell surface receptor(s) resulting in IL-8 gene transcription, 2) interactions between OipA and the cag PAI, and 3) OipA structures and motifs responsible for IL-8 gene transcription.
In AIM 2, we will determine the correlation between in vitro - in vivo roles of OipA and the cag PAI in gastric injury using Mongolian gerbils and the gp130F759 knock-in mouse model. In gerbils, gastric mucosal transcription factors induced by Hp infection differ with respect to phase and effect on infection (e.g., AP-1 is induced early and results in inflammation and ulceration whereas NF- B and ISRE are induced late and result in atrophy). Our previous results are based on analysis of the whole gastric mucosa. Here, we propose to determine how OipA and the cag PAI induce CXC chemokines using isolated gastric epithelial cells. We will also use mice that lack the Src homology 2 domain of the Src homology 2 phosphatase (SHP-2) binding site on the IL-6 family co- receptor, gp130. In these mice, the signal transducer and activator of transcriptions (STATs) signaling is hyperactivated and SHP-2->AP-1 signaling is absent. Our preliminary data showing that Hp infection results in hyperproliferative tumors in this mouse model will be extended to further clarify the roles of OipA and the cag PAI in the gastroduodenal pathogenesis. We hypothesize that the early phase, where the epithelial cell-cell barrier is intact in vitro, will correlate with acute inflammation in vivo and the late phase, where the epithelial barrier is disrupted in vitro, will correlate with chronic inflammation, ulceration and carcinogenesis (i.e., when the architecture of the gastric epithelium is disrupted in vivo). The innovative focus and strategic approaches described in this application will yield new levels of understanding of the biology of Hp infections.

Public Health Relevance

Helicobacter pylori infection causes gastric inflammation, peptic ulcer disease, and gastric cancer. The work outlined in this application will use human gastric cells and animal models to identify the molecular mechanisms by which Helicobacter pylori virulence factors cause gastric inflammation and subsequent disease. This project will be able to identify novel therapeutic targets for the treatment of Helicobacter pylori infections and prevention of Helicobacter pylori-related diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK062813-10
Application #
8534093
Study Section
Host Interactions with Bacterial Pathogens Study Section (HIBP)
Program Officer
Hamilton, Frank A
Project Start
2002-12-01
Project End
2014-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
10
Fiscal Year
2013
Total Cost
$315,766
Indirect Cost
$110,055
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Aftab, Hafeza; Miftahussurur, Muhammad; Subsomwong, Phawinee et al. (2016) Helicobacter pylori antibiotic susceptibility patterns in Bangladesh: Emerging levofloxacin resistance. J Infect Dev Ctries 10:245-53
Miftahussurur, Muhammad; Yamaoka, Yoshio (2016) Diagnostic Methods of Helicobacter pylori Infection for Epidemiological Studies: Critical Importance of Indirect Test Validation. Biomed Res Int 2016:4819423
Thi Huyen Trang, Tran; Thanh Binh, Tran; Yamaoka, Yoshio (2016) Relationship between vacA Types and Development of Gastroduodenal Diseases. Toxins (Basel) 8:
Matsunari, Osamu; Miftahussurur, Muhammad; Shiota, Seiji et al. (2016) Rare Helicobacter pylori Virulence Genotypes in Bhutan. Sci Rep 6:22584
Trang, T T H; Nagashima, H; Uchida, T et al. (2016) RAD51 G135C genetic polymorphism and their potential role in gastric cancer induced by Helicobacter pylori infection in Bhutan. Epidemiol Infect 144:234-40
Hashinaga, Masahiko; Suzuki, Rumiko; Akada, Junko et al. (2016) Differences in amino acid frequency in CagA and VacA sequences of Helicobacter pylori distinguish gastric cancer from gastric MALT lymphoma. Gut Pathog 8:54
Uotani, Takahiro; Sugimoto, Mitsushige; Ichikawa, Hitomi et al. (2016) Prostate stem cell antigen gene TT genotype and development of intestinal metaplasia in Helicobacter pylori infection. J Dig Dis 17:20-7
Miftahussurur, Muhammad; Shrestha, Pradeep Krishna; Subsomwong, Phawinee et al. (2016) Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol 16:256
Nagashima, Hiroyuki; Yamaoka, Yoshio (2016) Reply to Pachathundikandi and Backert. J Infect Dis 214:167-8
Graham, David Y (2015) Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 148:719-31.e3

Showing the most recent 10 out of 144 publications